Multicenter, Randomized, Phase III Study of a Single Dose of IncobotulinumtoxinA, Free from Complexing Proteins, in the Treatment of Glabellar Frown Lines

2013 ◽  
Vol 39 (4) ◽  
pp. 551-558 ◽  
Author(s):  
Alastair Carruthers ◽  
Jean Carruthers ◽  
William P. Coleman ◽  
Lisa Donofrio ◽  
Timothy Flynn ◽  
...  
Keyword(s):  
Single Dose ◽  
Phase Iii ◽  
Complexing Proteins ◽  
Phase Iii Study

scholarly journals Treatment of Bacterial Vaginosis: A Multicenter, Double-Blind, Double-Dummy, Randomised Phase III Study Comparing Secnidazole and Metronidazole

2010 ◽  
Vol 2010 ◽  
pp. 1-6 ◽  
Author(s):  
Jean-Marc Bohbot ◽  
Eric Vicaut ◽  
Didier Fagnen ◽  
Michel Brauman
Keyword(s):  
Single Dose ◽  
Bacterial Vaginosis ◽  
Multiple Dose ◽  
Phase Iii ◽  
Routine Practice ◽  
Vaginal Fluid ◽  
Double Blind ◽  
Nugent Score ◽  
Phase Iii Study ◽  
To Receive

Objective. Multiple-dose metronidazole oral therapy is currently the reference treatment for bacterial vaginosis (BV). This double-blind, double-dummy, noninferiority study compared the efficacy of secnidazole, another nitroimidazole with pharmacokinetics allowing a single dose regimen, to this standard treatment.Methods. A total of 577 patients were randomized to receive metronidazole (500 mg, b.i.d for seven days) or secnidazole (2 g, once). Therapeutic cure at D28 was defined as the resolution of vaginal discharge, positive KOH whiff test, vaginal pH>4.5and Nugent score>7on Gram-stained vaginal fluid.Results. According to this primary endpoint, the single-dose secnidazole regimen was shown to be at least as effective as the multiple-dose metronidazole regimen (60.1% cured women vs59.5% , 95% confidence interval with a noninferiority margin of 10%:[−0.082;0.0094]). Safety profiles were comparable in both groups.Conclusion. The secnidazole regimen studied represents an effective, convenient therapeutic alternative that clinicians should consider in routine practice.

Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 9019-9019
Author(s):  
P. J. Hesketh ◽  
V. Moiseyenko ◽  
G. Rosati ◽  
A. Makhson ◽  
J. Levin ◽  
...  
Keyword(s):  
Single Dose ◽  
Nausea And Vomiting ◽  
Phase Iii ◽  
Phase Iii Study

Phase III Study Makes Case for IV Chemoradiation

2007 ◽  
Vol 38 (1) ◽  
pp. 46-47
Author(s):  
BRUCE WILSON
Keyword(s):  
Phase Iii ◽  
Phase Iii Study

Treatment of Genotype 1 HCV Treatment-Naïve Patients: final results of phase III study ADVANCE

2011 ◽  
Vol 49 (01) ◽  
Author(s):  
T Berg ◽  
P Buggisch ◽  
P Malinski ◽  
H Diepolder ◽  
S Mauss ◽  
...  
Keyword(s):  
Phase Iii ◽  
Genotype 1 ◽  
Hcv Treatment ◽  
Treatment Naïve ◽  
Phase Iii Study
Sign in / Sign up

Export Citation Format

Share Document